Kevin Hakimi, a medical student at the University of California San Diego School of Medicine, discusses the rationale for the phase 2 PADRES trial (NCT03438708) in clear cell renal cell carcinoma (RCC).

The PADRES trial was a single-arm study that evaluated the role of axitinib (Inlyta) in patients with clear cell RCC who could be good candidates for a partial nephrectomy but could not undergo the procedure due to anatomic considerations and renal function concerns.

Up to 25% of patients who present with RCC also have a form of chronic kidney disease or an estimated glomerular filtration rate of less than 60, and PADRES aimed to enroll patients with highly complex renal masses, Hakimi says. Resecting these types of large masses in patients with underlying kidney problems could lead to patients seeing their kidney condition worsen following surgery, Hakimi explains.

In PADRES, patients received neoadjuvant axitinib for approximately 8 weeks with the hope of reducing tumor size of their tumors to allow for a partial nephrectomy while preserving renal function in patients that already have chronic kidney disease, Hakimi concludes.

Videos

Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.


Kevin Hakimi

Articles

Kevin Hakimi on the Rationale of the PADRES Trial in RCC